The Claim
Baseline body mass index (BMI) is inversely associated with percent weight change during GLP-1 receptor agonist therapy, such that individuals with higher baseline BMI experience a smaller percentage of weight loss, as quantified by a meta-regression coefficient of β = +0.46 (p < 0.001).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with a higher starting body mass index tend to lose a smaller percentage of their body weight when taking GLP-1 receptor agonist medications. For every unit increase in baseline BMI, the percent weight loss decreases by 0.46 percentage points.
See the scientific wording
Baseline body mass index (BMI) is inversely associated with percent weight change during GLP-1 receptor agonist therapy, meaning that individuals with higher baseline BMI tend to experience a smaller percentage of weight loss, as indicated by a meta-regression coefficient of β = +0.46 (p < 0.001).
GLP-1 receptor agonists reduce appetite by acting on the brain. People with higher baseline BMI often have changes in hunger signaling that make this effect weaker, so they lose a smaller percentage of their body weight.
What the research says
1 studyThe study found that people with a higher starting weight tend to lose a smaller percentage of their weight when taking GLP-1 drugs, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.